P-225 - Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial.
Saved in:
| Title: | P-225 - Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial. |
|---|---|
| Authors: | Javle, M.1 (AUTHOR), Borbath, I.2 (AUTHOR), Clarke, S.3 (AUTHOR), Hitre, E.4 (AUTHOR), Louvet, C.5 (AUTHOR), Macarulla, T.6 (AUTHOR), Oh, D.7 (AUTHOR), Spratlin, J.8 (AUTHOR), Valle, J.9 (AUTHOR), Weiss, K.10 (AUTHOR), Berman, C.11 (AUTHOR), Howland, M.11 (AUTHOR), Ye, Y.11 (AUTHOR), Cho, T.11 (AUTHOR), Moran, S.11 (AUTHOR), Abou-Alfa, G.12 (AUTHOR) |
| Source: | Annals of Oncology. 2019 Supplement, Vol. 30, piv62-iv62. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1093/annonc/mdz155.224 |
